Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Some 560,000 children below 10 years old were vaccinated in Gaza in the midst of destruction, with health workers deeming the ...

The convergence of multiple flu strains in one animal can allow new virus strains to form—just as they did in past pandemics.

Discover the latest updates on the Global Fund's efforts in combating AIDS, Tuberculosis, and Malaria amidst challenges posed ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Peter Sands, head of the Global Fund, warned that climate change and conflict could undermine health improvements. Despite progress, funding concerns persist for 2026-2028 efforts. The 2024 report ...

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...

Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

It could be a real breakthrough for people at risk for HIV infection: A shot given every 6 months that reduces their risk by a whopping 96%.